Impax Pharmaceauticals has reported positive results in the latest clinical study of one of its treatments for Parkinson's disease, named IPX066.
The late-stage study on 471 people saw the drug meet key goals, including significantly improved control of motor symptoms compared with immediate-release carbidopa-levodopa (IR CD-LD).
IPX066 demonstrated an improvement over IR CD-LD in the proportion of "off time" during waking hours, during which medication has worn off and there is a return of Parkinson's disease symptoms.
Dr Suneel Gupta, chief scientific officer at Impax Pharmaceuticals, said the company is "excited" about the results, which show the drug provides a "robust level of efficacy".
"There is a major unmet need in patients with advanced [Parkinson's disease] for a therapy that can consistently extend and improve motor symptom control through the day and enhance quality of life," added Dr Robert A Hauser of the University of South Florida.
The news follows a study in the Archives of Neurology, which indicated that people with Parkinson's disease have a high incidence of vitamin D insufficiency.
Find the nearest Barchester nursing home.